SCHEMBL5495846

SCHEMBL5495846

O=C(NCCN1CCOCC1)Nc1ccc(Nc2ncc(-c3ccsc3)cn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.55
CNR1 P21554 2/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 2/20 0.48
KDR P35968 3/20 0.47
EPHX2 P34913 4/20 0.47
NAMPT P43490 1/20 0.46
PDGFRB P09619 2/20 0.44
FLT1 P17948 2/20 0.44
CHEK1 O14757 1/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
PRMT3 O60678 1/20 0.44
EGFR P00533 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14342346 0.91 PDPK1 (0.52) SMN1; SMN2CNR1LMNAKDREPHX2
SCHEMBL5499148 0.88 MEN1 (0.43) SMN1; SMN2CNR1LMNAMAPTCHEK1
SCHEMBL5494719 0.84 ATM (0.52) SMN1; SMN2LMNAMAPTEGFR
SCHEMBL5499970 0.81 LIMK1 (0.48) CNR1MAPTPDGFRBTSHREGFR
SCHEMBL5500638 0.81 SMN1; SMN2 (0.53) SMN1; SMN2LMNAMAPTNAMPTGAA
SCHEMBL5526330 0.79 TSHR (0.43) MAPTEPHX2TSHREGFR
SCHEMBL5499927 0.79 LIMK1 (0.41) CNR1MAPTPRMT3EGFR
SCHEMBL13605383 0.79 KDR (0.58) KDRFLT1EGFR
SCHEMBL5500633 0.77 HDAC3 (0.41) EPHX2EGFR
SCHEMBL5500015 0.77 CHEK2 (0.42) SMN1; SMN2MAPTKDRFLT1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 SMN1; SMN2 3601/4885CNR1 2854/4885LMNA 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.